McKesson Corporation (NYSE:MCK) reached a new all-time high, with its stock closing at $737.0. The healthcare giant now boasts a market capitalization of $92 billion, supported by a robust 25.31% increase in stock value over the past year and strong revenue growth of 16.22%. This milestone highlights investor confidence in McKesson’s strategic initiatives and its ability to navigate the evolving healthcare landscape.
In recent earnings, McKesson reported Q3 2025 adjusted EPS of $10.12, exceeding analyst expectations of $9.81. However, revenue came in slightly below forecasts at $90.82 billion versus the anticipated $93.48 billion. The company also completed the acquisition of a 70% controlling stake in Core Ventures for approximately $2.49 billion, advancing its strategy to expand community-based oncology care.
Morgan Stanley raised its price target to $770 with an Overweight rating, while Jefferies lifted its target to $800, maintaining a Buy rating—both reflecting optimism about McKesson’s growth potential. Wells Fargo kept an Equal Weight rating with a $766 price target, citing a modest increase in full-year EPS guidance.
McKesson continues to streamline its portfolio, including plans to divest the MedSurg segment, focusing on strengthening its core U.S. Pharmaceutical business. The company’s long-term EPS growth forecast remains strong at 12% to 14%, underscoring its commitment to driving growth in healthcare services.